Abstract

The impact of concurrent fatty liver (FL) on response to antiviral therapy in chronic hepatitis B (CHB) patients has not been well characterized. We aimed to systematically review and analyse antiviral treatment response in CHB patients with and without FL. We searched PubMed, Embase, Web of Science and the Cochrane Library databases from inception to 31 May 2023 for relevant studies. Biochemical response (BR), complete viral suppression (CVS) and hepatitis B e antigen (HBeAg) seroconversion in CHB patients with FL (CHB-FL) and without FL (non-FL CHB) were compared. In an initial pool of 2101 citations, a total of 10 studies involving 2108 patients were included. After 12?weeks of treatment, CHB-FL patients as compared with non-FL CHB patients had lower BR rate (48.37% [108/227] vs. 72.98% [126/174], p?=?.04) but similar trend for CVS (36.86% [80/227] vs. 68.81% [114/174], p?=?.05) and similar rates of HBeAg seroconversion (6.59% [7/103] vs. 7.40% [7/110], p?=?.89). However, at week?48, there were no statistically significant differences between CHB-FL and non-FL CHB patients in any of the outcomes, including BR (60.03% [213/471] vs. 69.37% [314/717], p?=?.67), CVS (65.63% [459/746] vs. 73.81% [743/1132], p?=?.27) and HBeAg seroconversion (10.01% [30/275] vs. 14.06% [65/453], p?=?.58) with similar findings for week 96. BR rate was lower in CHB-FL patients after 12?weeks of antiviral treatment. However, after a longer follow-up of either 48 or 96?weeks, no statistically significant differences were observed in BR, CVS or HBeAg seroconversion rates between CHB patients with and without FL.

View details for DOI 10.1111/jvh.13942

View details for PubMedID 38590002